Franklin Resources Inc. Has $671.30 Million Position in Boston Scientific Corporation $BSX

Franklin Resources Inc. lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 9.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,875,933 shares of the medical equipment provider’s stock after selling 708,747 shares during the quarter. Franklin Resources Inc.’s holdings in Boston Scientific were worth $671,297,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Gerber Kawasaki Wealth & Investment Management grew its holdings in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC lifted its holdings in shares of Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares during the period. Claret Asset Management Corp lifted its holdings in shares of Boston Scientific by 4.4% during the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC grew its stake in shares of Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 103 shares during the last quarter. Finally, Scotia Capital Inc. grew its stake in shares of Boston Scientific by 0.7% in the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock worth $1,621,000 after purchasing an additional 104 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Morgan Stanley lowered their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a research note on Friday, February 6th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Wells Fargo & Company cut their price objective on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, Oppenheimer reduced their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $108.00.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $69.58 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm’s fifty day simple moving average is $83.51 and its two-hundred day simple moving average is $93.81. Boston Scientific Corporation has a 12 month low of $68.19 and a 12 month high of $109.50. The stock has a market capitalization of $103.24 billion, a P/E ratio of 35.86, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup cut its price target on BSX from $102 to $94 but kept a “buy” rating — signaling the firm still sees meaningful upside even after lowering near-term expectations. This preserves analyst support that can limit downside pressure. Citigroup Lowers PT
• Neutral Sentiment: Unusually large volume of put-option purchases was reported, indicating traders are hedging or speculating on further downside; this raises short‑term volatility but can reflect transient positioning rather than a change in fundamentals. Put Options Flow
• Negative Sentiment: Multiple law firms have filed or announced investigations and class actions against Boston Scientific covering purchases between July 23, 2025 and Feb 3, 2026; plaintiffs allege securities-law violations. A growing wave of litigation increases legal risk, potential discovery costs, and an overhang that often weighs on shares. Bronstein Class Action
• Negative Sentiment: Numerous plaintiff firms (including Rosen, Faruqi, RGRD, Bragar Eagel & Squire, and others) are soliciting lead-plaintiff motions and reminding shareholders of the May 4, 2026 deadline — amplifying publicity and the probability of consolidated litigation. That sustained media/legal attention typically pressures near-term sentiment and can increase legal-cost uncertainty. Deadline Reminder

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.